Stephen Ubl, PhRMA president and CEO (Adrien Villez for Endpoints News)
January 12, 2024 03:20 PM EST
Pharma
FDA+

PhRMA, Eli Lil­ly, oth­er drug com­pa­nies push back on FDA's draft guid­ance about com­mu­ni­cat­ing off-la­bel use

Lia DeGroot

Big Phar­ma is push­ing back on draft guid­ance pub­lished by the FDA this fall that aims to clar­i­fy how …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

A service from the Financial Times